| Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. We show 28 historical shares outstanding datapoints in our VYGR shares outstanding history coverage, used to compute VYGR market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VYGR market cap history over the course of time is important for investors
interested in comparing VYGR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VYGR versus a peer is one thing; comparing
VYGR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VYGR can fluctuate over the course of history.
With this page we aim to empower investors researching VYGR by allowing them to research the VYGR market cap history.